OPT - Why Is Retinal Diseases-Focused Opthea Stock Trading Higher Today? | Benzinga
Opthea Limited (NASDAQ: OPT) on Wednesday said it expects to receive the remaining $35 million committed funds under the Development Funding Agreement (DFA) with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional $50 million in funding.
Under the terms of the agreement, Carlyle and Abingworth committed $120 million, of which $85 million has been received to date.
The remaining committed funds of ...